Jubilant Ingrevia Limited — Updates, 27-10-2025: Press Release

Jubilant Ingrevia's recent quarter and half-year results show PAT up 18% YoY. Specialty Chemicals drove growth (revenue +12% YoY, EBITDA +44% YoY), fuelled by CDMO and 10+ new molecules with ₹1,200 Cr+ peak revenue potential. Chemical Intermediates achieved six-quarter high sales. Future accelerated growth is expected from CDMO orders & new facilities.